3,4,5-triphenyl-phthalic acid | 103050-88-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,4,5-triphenyl-phthalic acid
• 英文别名: 3,4,5-Triphenyl-phthalsaeure；3,4,5-Triphenylphthalic acid
• CAS: 103050-88-0
• 化学式: C₂₆H₁₈O₄
• 分子量: 394.427
• InChiKey: JEAQJTYJUMGUCD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  马来酸酐 、 4-hydroxy-2,3,4-triphenylcyclopent-2-ene-1-one 生成 3,4,5-triphenyl-phthalic acid 、 1,7,8-triphenyl-bicyclo[2.2.2]oct-7-ene-2,3,5,6-tetracarboxylic acid-2,3,5,6-dianhydride
  参考文献：
  名称：

  Polaczkowa et al., Roczniki Chemii, 1957, vol. 31, p. 115,118

  摘要：

  DOI：

文献信息

• [EN] NANOPARTICLES FOR PHOTODYNAMIC THERAPY, X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF<br/>[FR] NANOPARTICULES POUR THÉRAPIE PHOTODYNAMIQUE, THÉRAPIE PHOTODYNAMIQUE INDUITE PAR RAYONS X, RADIOTHÉRAPIE, CHIMIOTHÉRAPIE, IMMUNOTHÉRAPIE, ET TOUTE COMBINAISON DE CELLES-CI
  申请人：UNIV CHICAGO

  公开号：WO2016061256A1

  公开（公告）日：2016-04-21

  Metal-organic frameworks (MOFs) comprising photosensitizers are described. The MOFs can also include moieties capable of absorbing X- rays and/or scintillation. Optionally, the photosensitizer or a derivative thereof can form a bridging ligand of the MOF. Further optionally, the MOF can comprise inorganic nanoparticles in the cavities or channels of the MOF or can be used in combination with an inorganic nanoparticle. Also described are methods of using MOFs and/or inorganic nanoparticles in photodynamic therapy or in X-ray induced photodynamic therapy, either with or without the co-administration of one or more immunotherapeutic agent and/or one or more chemotherapeutic agent.

  金属有机框架（MOFs）包括光敏剂。MOFs还可以包括能够吸收X射线和/或闪烁的基团。可选地，光敏剂或其衍生物可以形成MOF的桥联配体。进一步可选地，MOF可以包括在MOF的腔或通道中的无机纳米粒子，或者可以与无机纳米粒子结合使用。还描述了在光动力疗法或X射线诱导的光动力疗法中使用MOFs和/或无机纳米粒子的方法，无论是否与一个或多个免疫治疗剂和/或一个或多个化学治疗剂联合给药。
• Complexes made using low solubility drugs
  申请人：Wong S.L. Patrick

  公开号：US20060134204A1

  公开（公告）日：2006-06-22

  Disclosed herein are substances that include a complex that includes a drug moiety ionically bound to a counter-ion; wherein a solubility of the complex is greater than a solubility of the drug moiety. Also disclosed are compositions and dosage forms made from such substances and complexes; methods of making compositions, substances, and complexes; and methods of administering the same to patients.

  本文揭示了一种物质，其中包括一种复合物，该复合物包括离子键合的药物基团和对离子；其中复合物的溶解度大于药物基团的溶解度。还揭示了由这种物质和复合物制成的组合物和剂型；制备组合物、物质和复合物的方法；以及将其用于患者的方法。
• Methods and dosage forms for controlled delivery of paliperidone and risperidone
  申请人：Yam V. Nyomi

  公开号：US20050232995A1

  公开（公告）日：2005-10-20

  Dosage forms and methods for providing a substantially ascending rate of release of paliperidone or risperidone are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma paliperidone or risperidone concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma paliperidone or risperidone concentration occurrence in each 24 hour period. In addition, the peak plasma paliperidone or risperidone concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma paliperidone or risperidone concentration that occurs following administration of paliperidone or risperidone in an immediate-release dosage form.

  本发明提供了用于提供相对升高的帕利哌酮或利培酮释放速率的剂型和方法。这种持续释放的剂型在每天一次的给药时提供治疗有效的平均稳态血浆帕利哌酮或利培酮浓度。这种一天一次的给药方案只会在每24小时内发生一次峰值血浆帕利哌酮或利培酮浓度。此外，峰值血浆帕利哌酮或利培酮浓度发生在给药后的较晚时间，并且比即时释放剂型的峰值血浆帕利哌酮或利培酮浓度具有较小的幅度。
• [EN] METHODS AND DOSAGE FORMS FOR CONTROLLED DELIVERY OF PALIPERIDONE<br/>[FR] TECHNIQUES ET FORMES DE DOSE D'APPORT COMMANDE DE PALIPERIDONE
  申请人：ALZA CORP

  公开号：WO2004010981A1

  公开（公告）日：2004-02-05

  Dosage forms and methods for providing a substantially ascending rate of release of paliperidone are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma paliperidone concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma paliperidone concentration occurrence in each 24 hour period. In addition, the peak plasma paliperidone concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma paliperidone concentration that occurs following administration of paliperidone in an immediate-release dosage form.

  提供了用于提供相对上升速率的帕利哌酮释放的剂型和方法。持续释放的剂型在每天一次给药时提供治疗有效的平均稳态血浆帕利哌酮浓度。这种一天一次的给药方案导致每24小时期间仅出现一次峰值血浆帕利哌酮浓度。此外，峰值血浆帕利哌酮浓度发生在剂量给药后的较晚时间，并且比使用即时释放剂型的帕利哌酮给药后发生的峰值血浆帕利哌酮浓度小。
• Methods of Reducing Alcohol-Induced Dose Dumping for Opioid Sustained Release Oral Dosage Forms
  申请人：Sathyan Gayatri

  公开号：US20090221621A1

  公开（公告）日：2009-09-03

  Disclosed are methods of sustained release administration of opioids, including but not limited to hydromorphone and oxycodone, that exhibit improved properties with respect to co-ingestion with aqueous alcohol.

  本发明涉及一种持续释放阿片类药物的给药方法，包括但不限于羟吗啡和氧化可酮，其在与水性酒精共同摄入方面表现出改善的特性。